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Abstract
Purpose: In order to elucidate anticancer effects of monocarbonyl analogs of curcumin (MACs), we have undertaken the present
study to obtain information regarding drug targets by using a microarray approach, and to study the cellular localization of EF24
and the activity of two key transcription factors, AP-1 and NF-κB, involved in complex cellular responses of cell survival and
death. Methods: Cytotoxic activity of various drugs was evaluated using a Neutral Red Dye assay. Cellular localization of bioti-
nylated EF24 (active) and reduced EF24 (inactive) was determined using light and confocal microscopy. Measurement of tran-
scription factor binding was carried out using Transfactor ELISA kits (BD Clontech, Palo Alto, CA). Gene microarray processing
was performed at Expression Analysis, Inc (Durham, NC) using Affymetrix Human U133A Gene Chips. Results: In this study, we
demonstrated that EF24 and UBS109 exhibit much more potent cytotoxic activity against pancreatic cancer than the current
standard chemotherapeutic agent gemcitabine. EF24, rapidly localizes to the cell nucleus. The compound modulates the DNA
binding activity of NF-κB and AP-1 in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. Im-
munohistochemical studies utilizing biotinylated-EF24 and chemically-reduced EF24 show that the unsaturated compound and
biotinylated EF24, but not reduced EF24, translocates to the nucleus within 30 minutes after the addition of drug. Through a gene
microarray study, EF24 is shown to affect genes directly involved in cytoprotection, tumor growth, angiogenesis, metastasis and
apoptosis. Conclusion: EF24 and UBS109 warrant further investigation for development of pancreatic cancer therapy. The dual-
istic modulations of gene expression may be a manifestation of the cell responses for survival against oxidative stress by EF24.
However, the cytotoxic action of EF24 ultimately prevails to kill the cells.
Keywords:Curcumin Analogs; EF24; UBS109; Pancreatic, Breast and Prostate Cancers; Oxidative Stress; Nuclear Translocation;
NF-κB; AP-1
Introduction
Curcumin (diferuloylmethane, Figure 1) a major component
of turmeric, is used as a coloring and flavoring agent in many
food items including curries and mustards. Although curcu-
min has traditionally been used in Indian folk medicine for a
wide range of ailments, recent pre-clinical and clinical studies
demonstrate that this phytochemical also exhibits an array of
anticancer properties.1 The pharmacological safety of curcu-
min has been demonstrated by its consumption for centuries
at average human levels of 100-200 mg/day to as high as 12
g/day in toxicity studies.2 One potential problem with the
clinical use of curcumin is its low potency, poor absorption
and limited stability 3, 4; however, curcumin remains an ideal
lead compound for the design of more effective analogs.5
A recent review has examined the anticancer and an-
ti-inflammatory actions of a wide range of monocarbonyl
analogs of curcumin (MACs).5 We have found that four
MACs with a common mechanism of action, including EF24,
EF25, EF31 and UBS109, may be clinically useful.6-12
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FIG. 1: Chemical structures of curcumin and analogs (MACs).
Here, we summarize tumorigenic actions of the subset of
MACs considered in this work. EF24, EF25, EF31 and UBS109
inhibit a wide variety of cancer cells.6-8, 10, 13-16 MACs also
mediate inflammation 9, disrupt the microtubule cytoskeleton
and inhibit HIF-1 17, in contrast to paclitaxel, which involves
stabilization of cellular microtubules, thereby interfering
with normal microtubule dynamics during cell division.
Tissue factor (TF) is aberrantly expressed in cancer and its
vasculature and causes thrombo-embolic complications. As a
complement to direct administration of the MAC molecules,
we have developed a method to specifically deliver EF24 and
paclitaxel to TF-expressing tumor endothelia and breast
cancer cells in subcutaneous and lung metastasis models by
conjugating the drugs to factor VIIa. The drug conjugates
complex with TF at the cell surface followed by endocytosis
of the protein aggregate and cleavage of the drugs in the
cytoplasm.18-22
FIG. 2: The 2D structure of the acetate salt of EF24.
The MAC analog, 3,5-bis[(2-fluorophenyl)methylene]
-4-piperidinone acetate (EF24, NSC 716993), exhibits broad
spectrum activity in both our screening and that of the NCI
anticancer 60 cell line panel, as well as potent anti-angiogenic
activity in a HUVEC cell migration assay.23 EF24 has been
administered at 10 mg/kg by iv, ip and oral gavage. EF24
plasma stability, protein binding, pharmacokinetics (PK), and
metabolism were characterized by LC/MS/MS assays. Plasma
protein binding is >98% with preferential binding to albumin.
EF24 bioavailability is 60 and 35% after oral and i.p. admin-
istration, respectively.24 After i.p. administration of EF31 at
concentrations of 12.5 and 25 mg/kg, peak mouse plasma
concentrations were reached at 0.25 and 0.5 hours post-dose
(Tmax), respectively. For UBS109 administered at 50 and 150
mg/kg by gavage, peak mouse plasma concentrations were
reached at 0.5 and 0.3 hours post-dose (Tmax), respectively.
In spite of the fact that UBS109 reduces tumor growth in
mice, the compound is quickly metabolized in vitro and 94%
protein bound in mouse plasma. The primary monounsatu-
rated metabolite is only modestly bioactive against
MDA-MB-231 breast cancer cells. These observations suggest
that while the α,β-unsaturated ketone common to curcumin
analogs is important for bioactivity, protein binding and
tissue distribution may serve to protect UBS109 from full
metabolism in vivo, while allowing it to exert a pharmaco-
logical effect by means of slow drug release.8, 25
We demonstrated that oxidative stress is one of the main
mechanisms of anti-cancer activity for MACs. EF24 and
UBS109 are electrophilic molecules, α,β-unsaturated ketone
Michael acceptors and reversibly bind the sulfhydryl group of
cysteine (Michael addition) of target proteins, thereby oxi-
dizing the thiol and inducing oxidative stress, whereas cur-
cumin either does not bind GSH or does so weakly and tran-
siently 26, 27 to act as an overall antioxidant. The redox state of
the cell is primarily a consequence of the precise balance
between the levels of ROS and endogenous thiol buffers
present in the cell, such as glutathione (GSH) and thioredoxin
(Trx). EF24-induced oxidative stress is evidenced by an in-
crease of reactive oxygen species (ROS) production, depletion
of glutathione GSH, its oxidized form, GSSG, and Trx in cells
with and without overexpression of Bcl-XL. Oxidative stress
induces mitochondrial membrane depolarization and subse-
quently activates caspases-9 and -3 activation, surface phos-
phatidylserine (PS) exposure, DNA fragmentation and apop-
totic cell death in both breast and prostate cancer cells.28, 29
Since Michael addition is one of the key mechanisms of
EF24’s chemical action, we anticipate that there will be many
molecular targets for EF24.23, 28, 30-32
While many investigators have documented a variety of
bioactions and molecular targets of curcumin 33 and its ana-
logs, the actual target(s) for these drugs are not well defined.
Mainly, studies have focused on the ability of curcumin to
inhibit the activities of transcription factors such as nuclear
factor kappa B (NF-κB).34-36 Both activator protein 1 (AP-1)
and NF-κB have been implicated in the process of carcino-
genesis and are constitutively activated in a number of cancer
cell lines.37-39 Several genes that are involved in cellular
transformation, proliferation, angiogenesis, invasion, and
metastasis are regulated by AP-1 40 and NF-κB.38 Thus, mod-
ulation of their activity may be an effective strategy against
cancer. AP-1 is a heterodimeric transcription factor com-
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posed of proteins belonging to the c-Fos, c-Jun, activating
transcription factor (ATF) and jun dimerization protein (JDP)
families. AP-1 binds to the TRE (TPA DNA responsive ele-
ment) motif and upregulates transcription of the genes con-
taining TRE. AP-1 regulates gene expression in response to
signals generated by a wide array of extracellular stimuli
including growth factors, tumor promoters, neurotransmit-
ters, UV light and cytokines and, in addition, controls a
number of cellular processes including differentiation, pro-
liferation, and apoptosis.40 NF-κB is an inducible and ubiq-
uitously expressed transcription factor for genes involved in
cell survival, cell adhesion, inflammation, differentiation and
growth. Active NF-κB complexes are dimers of various com-
binations of the Rel family of polypeptides consisting of p50
(NF-κB1), p52 (NF-κB2), c-Rel, v-Rel, Rel A (p65) and Rel
B.38 AP-1 and NF-κB have also been demonstrated to affect
the process of apoptosis.41-47 Apoptosis is characterized by
numerous biochemical and morphological changes in the cell
including surface PS exposure, caspase activation (particularly
caspase-3), cytoplasmic shrinkage and DNA fragmentation.
Studies suggest that both oxidative stress and changes in the
mitochondrial membrane potential are causal agents of
apoptosis.46, 47
Mechanistically, MACs (EF24) potently suppress the NF-κB
signaling pathway by direct action on IκB kinase (IKK).48 In a
screen of 50 kinases relevant to many forms of cancer, EF31
showed ≥85% inhibition of 10 of the enzymes at 5 μM, while
22 of the proteins were blocked by ≥40%. These MACs are
pleiotropic inhibitors that operate at multiple points along
cell signaling pathways, show selectivity for serine/threonine
kinases and compete with ATP.49 In a related study, EF24 was
found to be a strong inhibitor of FANC-D2-Ub and therefore
a regulator of Fanconi anemia (FA). Studies suggest that MAC
drugs target the FA pathway through blockade of IKK.50
In concert with manipulation of NF-κB in the cytoplasm,
EF24-induced decrease of lung cancer cell viability is known
to be accompanied by upregulation of mitogen-activated
protein kinases (MAPKs) as evidenced by increased phos-
phorylation of ERK1/2, JNK and p38. Indeed, we have
demonstrated that a combination of EF24 and SB203580, a
p38 inhibitor, synergistically inhibits clonogenic activity of
A549 lung cancer cells while inducing apoptosis and the
accumulation of the sub-G1 fraction of cells.51 In parallel,
EF31 increases basal levels of MAPK transcription fac-
tor-DNA binding in mouse RAW264.7 macrophages.9
To elucidate a global view of the anticancer/cytocidal actions
of these compounds, we sought information regarding their
drug targets by using microarrays, and examined cellular
localization of EF24 and the activity of two key transcription
factors, AP-1 and NF-κB, essential for cell survival and death.
Methods and Materials
Cell culture
Mia-PaCa-2, ASPC-1, Pt45P1, MDA-MB-231, and DU-145
cells were cultured as described. 28, 52, 53 Neutral Red Dye assay
was used for the cytotoxic activity of drugs.8
Synthesis of biotinylated EF24 analogs
Biotinylated 3,5-bis-(2-fluorobenzylidene)-piperidin-4-one
(Figure 3A): Under argon, 50.0 mg (0.20 mmol) of D-biotin
(Figure 3C) and 65.0 mg (0.20 mmol) of the curcumin deriv-
ative, 3,5-bis-(2-fluorobenzylidene)-piperidin-4-one, were
suspended in 0.6 mL of dimethylyformamide (DMF). Hy-
droxybenzotriazole (54.0 mg, 0.40 mmol) was added and after
cooling the reaction mixture to 0oC, 0.22 mL (1.0 M in
CH2Cl2, 0.22 mmol) of 1, 3-dicyclohexylcarbodiimide was
added. The reaction mixture was stirred overnight at room
temperature. The white solid that formed was filtered off, and
the solvent was removed under vacuum. The crude product
was purified by preparative HPLC (C18 DYNAMAX column;
UV detector 254 nm; 1. run: flow rate: 8 mL, solvent system:
80% water - 20% acetonitrile --> 20% water -80% acetonitrile
within 50 minutes, retention time: 38.6 minutes; 2. run: flow
rate: 12 mL, solvent system: 70% water – 30% acetonitrile -->
30% water – 70% acetonitrile within 50 minutes, retention
time: 37.1 minutes). Yield (crude): 95.7 mg (89%); Yield: 15.1
mg (14%); 1H NMR (400 MHz, CD3COCD3)  7.86 - 7.83 (2H,
m), 7.64 – 7.50 (4H, m), 7.39 – 7.25 (4H, m), 5.80 (1H, bs),
5.71 (1H, bs), 4.87 (2H, s), 4.82 (2H, s), 4.46 (1H, t, J = 7.6),
4.82 (1H, t, J = 5.2), 3.12 – 3.08 (1H, s), 2.90 (1H, dd, J1 = 12.8,
J2 = 5.2), 2.67 (1H, d, J = 12.8), 2.21 (2H, t, J = 7.6), 1.62 – 1.19
(6H, m); 13C NMR (100 MHz, CD3COCD3) 185.76, 171.45,
163.50, 161.16, 134.78, 132.14, 131.33, 129.07, 124.99, 116.23,
115.87, 61.68, 60.15, 55.764, 46.68, 43.16, 40.33, 32.43, 25.09,
24.95; Fast Atom Bombardment Mass Spectroscopy (FABMS):
m/z 544.7 ([M+Li]+, C29H29F2LiN3O3S requires 544.5).
FIG. 3: The structures of biotinylated EF24, C=O reduced biotinylated EF24 analog, and D-biotin.
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Biotinylated 3,5-bis-(2-fluorobenzylidene)-piperidin-4-ol
(Figure 3B) : Under argon, 45.8 mg (186.0 mol) of cerium
(III) chloride was suspended in 1 mL of methanol. At room
temperature, 100.0 mg (186.0 mol) of biotinylated
3,5-bis-(2-fluorobenzylidene)-piperidin-4-one was added to
the suspension and followed 5 minutes later by 7.03 mg
(186.0 mol) of sodium borohydride. The reaction mixture
was stirred for 30 minutes at room temperature. After filtra-
tion, the solvent was removed, and the crude product purified
by column chromatography (silica gel, ethyl acetate). A white
solid was obtained in 86% yield (86.3 mg). 1H NMR (400
MHz, CD3COCD3)  7.53 – 7.50 (2H, m), 7.39 – 7.710 (8H, m),
6.78 (2H, s), 6.05 (1H, bs), 6.01 (1H, bs), 5.89 (1H, s), 4.62 –
4.24 (6H, m), 3.13 – 3.08 (1H, m), 2.91 – 2.87 (1H, m), 2.68
(1H, d, J = 12.8), 2.10 – 2.04 (2H, m), 1.60 – 1.17 (6H, m); 13C
NMR (100 MHz, CD3COCD3) 171.04, 163.34, 140.92,
131.04, 129.74, 129.30, 124.61, 124. 38, 116.30, 115.87,
115.65, 115.51, 115.29, 74.367, 61.64, 60.16, 55, 79, 45.52,
41.88, 40.33, 32.58, 28.19, 24.94; High Resonance Fast Atom
Bombardment Mass Spectroscopy (HRFABMS): m/z 546.221
([M+Li]+, C29H31F2LiN3O3S requires 546.221).
Light and confocal microscopy immunohistochemistry
For the light microscopy experiments, MDA-MB-231 breast
cancer cells were plated on Lab-Tek 8 chamber glass slides
(Nunc, Inc., Naperville, IL). Following an overnight incuba-
tion, the cells were treated with DMSO, 10 M D-Biotin
(Figure 3C), 10 M EF24, 10 M EF24-Biotin (Figure 3A) and
10 M reduced EF24-Biotin (Figure 3B) for 6 hours. The
media was aspirated and the cells were fixed by adding 2%
formaldehyde in PBS for 15 minutes. After a final wash with
PBS, the slides were ready to be stained. Avidin-Biotin
Complex (ABC) (Vector Laboratories, Burlingame, CA) and 3,
3’-diaminobenzidine tetrahydrochloride (DAB, 0.025%;
Sigma Chemical Company, St Louis, MO) staining were car-
ried out according to the procedure of Vector Laboratories.
All imaging was performed using a Leica DMRB light micro-
scope (Leica Microsystems, Bannockburn, IL) coupled to a
Leica DC500 digital camera system.
For the confocal microscopy experiments, MDA-MB-231
cells were plated on Lab-Tek 8 chamber glass slides. Follow-
ing an overnight incubation, the cells were treated with 10
M D-biotin, 10 M EF24-biotin, and 10 M reduced
EF24-biotin for various periods of time. The media was aspi-
rated and the cells were washed and fixed by adding a solu-
tion of 0.5% Triton X-100 and 3.7% formaldehyde in PBS for
15 minutes. After washing twice with PBS, the cells were
washed with a solution of 1% BSA in PBS and then prepared
for staining. Streptavidin-FITC (Molecular Probes, Eugene,
OR) was diluted into the same solution of 1% BSA in PBS and
added to the wells for 45 minutes at room temperature. The
cells were washed twice with PBS and then once with 2x SSC
solution which is diluted from 20x SSC solution. DNAse free,
RNAse in 2x SSC solution (final concentration 10 g/ml) was
then added and the cells were incubated for 20 minutes at
37oC. Next, the cells were washed multiple times with 2x SSC
and then the nuclear stain, propidium iodide (Molecular
Probes, Eugene, OR), was added to the wells for 5 minutes at
room temperature. The cells were washed with 2x SSC solu-
tion, and then Antifade equilibration buffer (Molecular
Probes, Eugene, OR) was added for 5 minutes. The chambers
were then removed, and coverslips were placed on the slides
using Antifade reagent. All imaging was performed with the
green (488 nm) and red (543 nm) channels of a Zeiss LSM 510
confocal laser scanning microscope (Thornwood, NY) cou-
pled to a Zeiss Axioplan 2 imaging MOT and a 100X
plan-Apochromat oil immersion lens.
Measurement of transcription factor binding to DNA
This assay was performed in a manner similar to that previ-
ously described.9, 54-56 DU-145 and MDA-MB-231 cells were
grown on 16 cm2 dishes until 85% confluent. After treatment
with EF24 or DMSO for 3 hours, the cells were trypsinized
and collected into flow cytometry tubes and centrifuged to
obtain a cell pellet. Nuclear extracts were then isolated ac-
cording to the protocol described by Clontech (Palo Alto, CA)
using their Transfactor Nuclear Extraction Kit. The cells were
trypsinized and collected into centrifuge tubes, pelleted by
spinning for 5 minutes at 1,000 rpm, and the supernatant was
discarded. The cells were then rinsed by resuspending in an
equal volume of cold PBS, centrifuged (as above), and the
supernatant was discarded. Next, the cells were lysed in lysis
buffer containing 100 mM HEPES (pH 7.9), 15 mM MgCl2,
100 mM KCl, 0.1M dithiothreitol (DTT), and protease inhib-
itor cocktail (Sigma, St. Louis, MO) for 15 minutes on ice.
After centrifuging the suspension and discarding the super-
natant, the cells were disrupted by passing them through a
narrow-gauge (No. 27) needle ten times. The disrupted sus-
pension was then centrifuged at 11,000 rpm for 20 minutes,
and the supernatant/cytosolic fraction was collected. Next,
the crude nuclear pellet was suspended in Extraction Buffer
containing 20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.42 M
NaCl, 0.2mM EDTA, 25% (v/v) glycerol, 0.1 M DTT, and
protease inhibitor cocktail and the cells were passed through
a narrow gauge (No. 27) needle ten times to disrupt the nu-
clei. After shaking the nuclear suspension for 30 minutes at
4oC, the suspension was centrifuged at 14,000 rpm for 10
minutes. The supernatant/nuclear fraction was transferred to
a clean chilled microfuge tube. The nuclear extracts were
then tested for AP-1 and NF-B transcription factor binding
activity according to the procedures of the Transfactor ELISA
Kit (BD Clontech, Palo Alto, CA). 30 g of the nuclear ex-
tracts in 1X Transfactor/Blocking Buffer were added to a 96
well plate containing consensus DNA binding sequences for
AP-1 and NF-B. The sequences used were as follows: c-Fos
and c-Jun- TGACTCA; NF-B p50- GGGGATCCC; NF-B
p65- GGGGTATTTCC. Following incubation for 1 hour at
room temperature, the wells were washed three times with
1X Transfactor/Blocking Buffer. Primary antibodies for
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NF-B p50, NF-B p65, c-Fos, and c-Jun were then added to
their respective wells and the plate was incubated for 1 hour
at room temperature. After washing the wells three times
with 1X Transfactor/Blocking Buffer, secondary antibodies
were added to the wells. Both Anti-rabbit IgG-HRP and
Anti-mouse IgG-HRP were used according to the source of
the primary antibody. The wells were then incubated with
secondary antibody for 30 minutes at room temperature and
washed four times with 1X Transfactor Buffer. Tet-
ra-methylbenzidine (TMB) substrate was then added to the
wells for 10 minutes, and the reaction stopped by adding 25
µL of 1M H2SO4. The absorbance of the plate was measured at
450 nm with a Bio-Tek microplate reader (Bio-Tek Instru-
ments, Winooski, VT).
Gene microarray
MDA-MB-231 cells were grown on 16 cm2 dishes to near
confluency. The cells were then treated with either DMSO
for 24 hours or 2.5 M EF24 for 4, 14, and 24 hours. Three
separate replicates were performed for each of the experi-
mental conditions. Total RNA was then isolated using the
RNeasy mini kit from Qiagen (Valencia, CA). The cells were
lysed directly in the culture dish using Buffer RLT without
β-mercaptoethanol and collected. The samples were then
homogenized using QIAshredder spin columns (Qiagen,
Valencia, CA), mixed with 70% ethanol, added to RNeasy
mini columns, and centrifuged for 15 seconds at 10,000 rpm.
The flow-through was discarded, Buffer RW1 added, and the
samples were centrifuged as above. This process was then
repeated twice using Buffer RPE. To elute the RNA,
RNase-free water was added to the RNeasy columns and the
samples were centrifuged for 1 minute at 10,000 rpm. The
concentration of total RNA was adjusted to a final concen-
tration of 1 g/L.
Microarray processing was performed at Expression Analysis,
Inc (Durham, NC) using Affymetrix Human U133A Gene
Chips according to protocols described in the "Expression
Analysis Technical Manual" prepared by Affymetrix, Inc
(Santa Clara, CA). The U133A GeneChips contain up to
22,500 probe sets of short oligonucleotides (25mers). Each
probe set contains 11-20 pairs of perfect match (PM) oligos
and mismatch (MM) oligos that differ by a single nucleotide.
Before target production, the quality and quantity of each
RNA sample was assessed using an Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA). Target was prepared
and hybridized. Total RNA (10 g) was converted into cDNA
using reverse transcriptase (Invitrogen, Carlsbad, CA) and a
modified oligo (dT) 24 primer that contains T7 promoter
sequences (GenSet, San Diego, CA). After first strand syn-
thesis, residual RNA was degraded by the addition of RNAse
H and a double stranded cDNA molecule was generated using
DNA polymerase I and DNA ligase. The cDNA was purified
and concentrated using a phenol:choloform extraction fol-
lowed by ethanol precipitation. The cDNA products were
incubated with T7 RNA polymerase and biotinylated ribo-
nucleotides using an In Vitro Transcription kit (Enzo Diag-
nostics, Farmingdale, NY). One-half of the cRNA product was
purified using an RNeasy column (Qiagen, Valencia, CA) and
quantified with a spectrophotometer. The cRNA target (20
g) was incubated at 94oC for 35 minutes in fragmentation
buffer (Tris, MgOAc, KOAc). The size of the fragmented
target was confirmed using an Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA). The fragmented cRNA
was diluted in hybridization buffer (MES, NaCl, EDTA,
Tween 20, Herring Sperm DNA, Acetylated BSA) containing
biotin-labeled OligoB2 and Eukaryotic Hybridization Con-
trols (Affymetrix, Santa Clara, CA). The hybridization cock-
tail was denatured at 99oC for 5 minutes, incubated at 45oC for
5 minutes and then injected into a prehybridized GeneChip
cartridge. The GeneChip array was incubated at 42oC for at
least 16 hours in a rotating oven at 60 rpm. GeneChips were
washed with a series of nonstringent and stringent solutions
containing variable amounts of MES, Tween 20, and SSPE.
The microarrays were then stained with streptavidin phyco-
erythrin, and the fluorescent signal was amplified using a
biotinylated antibody solution. Fluorescent images were
detected in an Agilent Gene Array Scanner (Agilent Tech-
nologies, Palo Alto, CA).
Statistical considerations
The expression data was extracted using the MicroArray Suite
software, version 5.0 (Affymetrix, Santa Clara, CA) and ana-
lyzed with a custom Two-Group Comparison program de-
veloped at Expression Analysis. The comparison software
removes transcripts that were declared "Absent" in all sam-
ples and calculates fold change and statistical significance
between groups of samples using the Student's t-test.
Results
In vitro potency of EF24 and UBS109: comparison to
gemcitabine and Akt/MAPK p38 inhibitors
Our groups have a long-standing interest in pancreatic ductal
adenocarcinoma (PDA), a highly lethal form of cancer for
which gemcitabine is currently used as a standard chemo-
therapeutic regimen. PDA pathobiology is marked by high
exposure of surface PS and up-regulation of full-length Tissue
Factor (flTF), an obligatory enzymatic cofactor for serine
protease fVIIa and the main trigger of blood clotting which,
together with high surface PS levels, is believed to be major
contributing factors to high rates of thrombosis in PDA.57 We
recently showed that a minimally coagulant alternatively
spliced form of TF (asTF), also expressed at high levels in PDA
lesions, promotes tumor growth and spread
non-proteolytically, acting as an integrin ligand.52 Because
both flTF and asTF contribute to tumor growth and spread, as
does PS, we sought to examine whether EF24 and/or UBS109
exhibit cytotoxic activity against four human PDA lines:
Mia-PaCa-2 (high surface PS, no fl/asTF); ASPC-1(low sur-
face PS, more flTF than asTF); Pt45P1 (medium surface PS,
6 Adams et al.: Anticancer effects of curcumin analogs International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Adams et al. ISSN 2330-4049
more flTF than asTF), and Pt45P1/asTF+ (medium surface
PS, flTF approximately equals asTF).52, 53, 58, 59 As shown in
Figure 4, EF24 as well as UBS109 exerts a significantly more
potent effect on all four PDA lines compared to gemcitabine,
Akt inhibitor MK-2206, and p38 MAPK inhibitor SB203580.
FIG. 4(a)
FIG. 4(b)
FIG. 4(c)
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FIG. 4(d)
FIG. 4: UBS109 and EF24 show more potent anti-cancer activity against PDA cells than gemcitabine. Effects of EF24, UBS109, gemcitabine and
inhibitors of Akt (MK-2206) and p38 MAPK (SB203580) against various PDA cell lines. (a) MiaPaCa-2, high surface PS, no fl/asTF; (b) ASPC-1, low
surface PS, more flTF than asTF; (c) Pt45p1, medium surface PS, more flTF than asTF; and (d) Pt45P1/asTF+, medium surface PS, flTF approximately
equals asTF.
Using a cell viability assay using Neutral Red Dye in vitro,
we compared UBS109 (pink) and EF24 (red) against other
chemotherapeutic agents, namely, gemcitabine (blue) used as
a standard chemotherapeutic regimen for treatment of pan-
creatic cancer, inhibitors of Akt (MK-2206, purple) and p38
MAPK (SB203580, brown) and vehicle control (navy blue).
All agents were dosed from 0.0009 to 20 µM.
EF24, EF31 and UBS109 do not kill normal MCF-10A breast
cells at the concentrations ranged from 0.0012 to 20 µM
(100% viable). EF24, EF31 and UBS109 are cytotoxic against
all cancer cells we tested. UBS109 is the most active and
killed 100% at the concentrations indicated in parenthesis
after cancer type, including KB-3-1 (squamous cell carcino-
ma; SCC) (UBS109, 1.2 µM), TU212 (SCC) (5 µM), MiaPaCa-2
(pancreatic cancer) (0.312 µM), SE-MEL-28 (melanoma)
(0.070 µM), RPMI-7951 (melanoma) (0.0195 µM),
MDA-MB-231 (breast) (0.312 µM), i.e., at concentrations
ranging from 0.0012 uM to 20 uM.8
Cellular localization of biotinylated EF24
After treatment with a biotinylated drug, a number of tech-
niques employing avidin and streptavidin can be used to
identify the cellular localization of the drug as well as its
molecular target(s). In order to identify the cellular localiza-
tion of EF24, biotin was attached to the compound (Figure
3A) and light and confocal microscopy were used to visualize
the cellular localization of the biotinylated molecule. It is
important to mention that the activity of the biotinylated
version of EF24 is comparable to that of the parent EF24 (data
not shown). MDA-MB-231 and DU-145 cells also express
flTF and/or asTF, possess PS-dependent TF activity, and are
used extensively in breast and prostate cancer research, re-
spectively.60-62 In light of breast and prostate cancer preva-
lence in the general population, we elected to conduct our
further studies using MDA-MB-231 and DU-145 cells. Figure
5 shows MDA-MB-231 cells treated with 10 µM EF24-biotin
for 6 hours and visualized using light microscopy. Intense
brown DAB staining seen in the nuclei of the cells indicates
that the compound enters the cell and binds to a target in the
nucleus (Figure 5D). The binding of EF24-biotin requires the
presence of EF24 since the biotin molecule (Figure 3C) itself
shows very little staining (Figure 5B). In addition, the binding
of EF24-biotin is specific, since the staining can be blocked by
an excess of EF24 (Figure 5E).
FIG.5: Determination of the cellular localization of biotinylated EF24
using light microscopy.
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MDA-MB-231 cells were treated with DMSO (A) 10 µM
biotin; (B) 10 µM EF24; (C) 10 µM biotinylated-EF24 for 6
hours (D). The cellular localization of the agents was visual-
ized using DAB (brown stain) at 40X (times) magnification
and 60X (times) magnification (inset in D). Brown staining
can be seen in the nuclei of the cells in D (see arrows) indi-
cating the likelihood of a nuclear target. Only slight back-
ground staining can be seen in A-C, demonstrating that EF24
is necessary for binding. In order to test the specificity of the
biotinylated drug, the cells were pretreated with 200 µM
EF24 for 30 minutes prior to treatment with 10 µM
EF24-biotin for 6 hours (E).
FIG. 6: Determination of the cellular localization of biotinylated
EF24 using confocal microscopy.
The localization of the drug in the nucleus was further con-
firmed by experiments using confocal microscopy. Figure 6
shows MDA-MB-231 cells treated with 10 µM EF24-biotin at
various times and visualized using streptavidin-FITC. Green
staining in the nuclei of the cells could be seen after only 30
minutes, and the intensity of the stain increased after 3 and 6
hours treatments (Figure 6B, 6C, 6D). This stain overlapped
with propidium iodide (PI), which is a well-known nuclear
stain. This suggests that the molecular target of EF24 is most
likely a nuclear protein(s) and/or DNA; however, see below.
The cells were treated with 10 µM D-biotin as a control, and
no green color could be seen in the nuclei of the cells (Figure
6A). In addition, a reduced derivative of EF24 that can no
longer act as a Michael acceptor was also biotinylated (Figure
3B). Since a key chemical action of EF24 is the covalent and
often reversible attachment of drug to protein through Mi-
chael addition, the reduced EF24 derivative was used to probe
whether this activity is necessary for cellular localization of
the drug. Treatment of cells with the latter produced a
staining pattern similar to control, suggesting that this com-
pound does not bind to cellular molecules (Figure 6E).
MDA-MB-231 cells were treated with biotin alone (A) 10 µM
biotinylated-EF24 for 30 minutes; (B) 3 hours; (C) 6 hours;
(D) or 10 µM reduced EF24-biotin for 6 hours (E). The cellu-
lar localization of the drugs was visualized using streptavi-
din-FITC (green fluorescence) and the nuclei of the cells were
stained using propidium idodide (PI) (red fluorescence) at
100X magnification. Each panel shows PI alone (top left),
streptavidin-FITC alone (top right), and both stains together
(bottom left). Panel B shows green staining in the nuclei of
the cells treated with EF24-biotin for 30 minutes that is not
present in the biotin-treated cells (Panel A) and the overlap of
the green and red stains produces an orange color in the
nuclei instead of red (see arrows). After 3 hours and 6 hours
treatment with EF24-biotin (Panels C and D), the green
staining in the nuclei has increased and, consequently, the
overlap of the green and red stains produces a bright orange
color. Panel E shows that reducing the ketone moiety in EF24
to an alcohol produces a staining pattern that is similar to that
of control (Panel A), suggesting that the conjugated carbonyl
is important for drug action.
Inhibition of NF-κB activity
NF-κB has been shown to be constitutively activated in many
cancer cell lines, including DU-145 and MDA-MB-231.42, 43
Several laboratories have demonstrated that curcumin is an
inhibitor of NF-κB DNA binding activity.34-36, 43 It has also
been established that curcumin does not directly inhibit
NF-κB-inducing kinase (NIK) or IκB kinase (IKK) activity,
but instead inhibits an upstream signal of NIK leading to IKK
activity.63 Activated NIK then phosphorylates and activates
the IKK complex. IKK is part of a multiprotein complex that
contains IKK-α and IKK-β subunits, both critical in mediating
in vitro cytokine-induced IκB phosphorylation.
We studied the effects of curcumin and EF24 on the DNA
binding activity of NF-κB using an ELISA format. This assay
is an effective measurement of transcription factor binding in
nuclear extracts of treated cells, producing similar results to
electrophoretic mobility shift assays (EMSA).54-56 The out-
comes in Figure 7 indicate that treatment of MDA-MB-231
cells and DU-145 cells with EF24 (10 µM) for 3 hours signif-
icantly inhibits the constitutive binding activity of both the
p50 and p65 subunits of NF-κB. Curcumin also inhibits
NF-κB DNA binding.
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MDA-MB-231 cells (A and B) and DU-145 cells (C and D)
were treated with 40 µM curcumin or 10 µM EF24 for 3 hours
and nuclear extracts were isolated and tested for NF-κB (p65
and p50 subunits) DNA binding activity as described in Ma-
terials and Methods. 500 ng of competitor oligonucleotide
was added to demonstrate the specificity of the binding reac-
tion. Bars indicate mean + SEM (n = 2- 4) of transcription
factor binding activity (absorbance 450 nm). Significant dif-
ference from control is denoted as * P < 0.05, ** P < 0.01, *** P <
0.001.
Induction of c-Fos/AP-1 activity
Since the antiproliferative effects of curcumin have been
attributed to an anti-AP-1 activity 34-36, we studied the effects
of our MAC on the DNA binding activity of this transcription
factor using the Transfactor ELISA assay as was used for
NF-κB. The treatment of breast and prostate cancer cells with
EF24 for 3 hours produced a more than 5-fold increase in the
DNA binding activity of c-Fos instead of a decrease in the
activity of AP-1 (Figure 8). However, the addition of EF24 to
a previously untreated nuclear extract did not increase c-Fos
or c-Jun binding activity in the ELISA assay, indicating that
the compound most likely effects the upstream activation of
the transcription factor and does not directly interfere with
DNA binding. In the same assay, curcumin, on the other
hand, inhibited both c-Jun and c-Fos in both cell lines, con-
firming results seen by others using the EMSA method.34, 35, 64
MDA-MB-231 cells (A and B) and DU-145 cells (C and D)
were treated with 40 µM curcumin or 10 µM EF24 for 3 hours
and nuclear extracts were isolated and tested for c-Fos and
c-Jun DNA binding activity as described in Methods and
Materials. 500 ng of competitor oligonucleotide was added to
demonstrate the specificity of the binding reaction. Bars
indicate mean + SEM (n = 2 - 4) of transcription factor bind-
ing activity (absorbance 450 nm). Significant difference from
control is denoted as * P < 0.05, ** P < 0.01, *** P < 0.001.
Effect of EF24 on cancer-related gene expression
Table 1 shows a list of cancer-related genes affected by EF24.
Genes important for angiogenesis, migration and metastasis,
such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), in-
terleukin-8 (IL-8), VEGF, urokinase plasminogen activator
(uPA) and cyclooxygenase-2 (COX-2), were all down regu-
lated after 4 hours EF24 treatment. Because all these genes
have been shown to be regulated by NF-κB 42, this decrease in
transcript levels supports the results in Figure 7 demonstrat-
ing that EF24 indirectly decreases the DNA binding activity
of NF-κB. Modulation of these genes may play a role in the
ability of EF24 to induce apoptosis and reduce breast tumor
size in vivo.28
FIG. 7: EF24 inhibits the DNA binding activity of NF-κB.
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FIG. 8: EF24 activates the DNA binding activity of c-Fos/AP-1.
TABLE 1: Modulation of cancer-related genes by EF24.
Genes Fold Change Time Function
Interleukin-1, beta -1.75 4h Angiogenesis, Osteoclast Activation
Interleukin-6 -2.12 4h Migration, Angiogenesis, Metastasis
Interleukin-8 -2.85 4h Angiogenesis
Vascular Endothelial
Growth Factor
-1.64 4h Angiogenesis
Urokinase Plasminogen
Activator
-1.95 4h Invasion, Migration, Metastasis
Cyclooxygenase-2 -2.55 4h Proliferation, Angiogenesis,
Metastasis
Heme Oxygenase-1 +22.6 4h Cytoprotection/Anti-carcinogenesis
Quinone Reductase +1.86 4h Cytoprotection/Anti-carcinogenesis
Quinone Reductase +2.13 14h
Quinone Reductase +2.01 24h
Treatment of the cells with EF24 also induced the upregula-
tion of genes that play a role in cytoprotection and an-
ti-carcinogenic activity. Strikingly, a 22-fold increase was
seen in the heme oxygenase-1 (HO-1) transcript after 4 hours.
HO-1 is an enzyme that contributes to the conversion of
heme to bilirubin, a bile pigment and active antioxidant. In
addition, treatment of the cells with EF24 induced a 2-fold
increase in the NAD (P) H quinone reductase gene (QR) after
4 hours, and this upregulation persisted over 14 hours (+2.13)
and 24 hours (+2.01). Quinone reductase is a phase II detox-
ifying enzyme that is important in fighting chemical carcin-
ogens. Both of these genes are regulated by AP-1 64, 65; thus,
this increase in transcript level supports the results in Figure
8, which show that EF24 induces AP-1 activity. The micro-
array data show that EF24 also increases gene expression of
several stress genes such as heat shock proteins (HSP)-40
(+2.4), HSP-60 chaperonin (+2.3), HSP-70 (+3.0), HSP-90
(+1.86), thioredoxin interacting protein (+2.28), and gluco-
corticoid receptor DNA binding protein (+2.5). Acting in
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concert, these genes may help the cells to survive oxidative
stress.
Discussion
We show here that EF24 and UBS109 are significantly more
cytotoxic against four PDA cancer cell lines compared to
gemcitabine. Our immunohistochemical studies reveal that
biotinylated EF24 rapidly localizes to the nuclei, while its
reduced biotinylated variant does not. This suggests that the
conjugated compound affects DNA binding activity of NF-κB
and c-Fos in the nuclear compartment of MDA-MB-231 and
DU-145 cells.
EF24 reduces the levels of DNA binding of both NF-κB p65
and p50 subunits and increases that of c-Fos, as demonstrated
by ELISA of the nuclear extracts from EF24-treated cells.9, 54-56
These results are consistent with the data previously demon-
strating that EF24 blocks NF-κB by suppressing IKK 37, while
curcumin inhibits NF-κB by blocking the pathway upstream
of NIK and IKK.63 However, EF24 has no effect on the DNA
binding activity of c-Fos when added directly to the un-
treated-nuclear extracts from either of the cell lines. EF24
increases the DNA binding of c-Fos, while curcumin (cur-
cumin-loaded polyvinylpyrrolidone nanoparticles), by con-
trast, inhibits both c-Fos and c-Jun, hence AP-1 binding.66
The precise molecular details are not yet in hand, but we
propose a hypothesis as to the basis for the staining of nuclear
proteins by biotinylated EF24, and the possibility that EF24
and related anti-cancer agents can relieve tumorigenic effects
by action in the nucleus. It appears that Michael addition is
necessary for EF24 to interact with its molecular target(s),
suggesting that its cytocidal actions and anti-proliferative
effects are dependent upon this mechanism. As to potential
targets of EF24, cysteine dioxygenase type 1, (CDO1), is a
DNA hypermethylated gene that determines the flux be-
tween cysteine catabolism and glutathione synthesis.  Inac-
tivation of CDO1 contributes to cancer cell survival.67 EF24
may not only capture glutathione and thioredoxin by Michael
addition 23, 28, 29 but the two closely related analogs (EF31 and
UBS109) are known to serve as DNA hypomethylating agents
in pancreatic cancer.10 Such drug action suggests the capacity
for silencing of CDO1 by reduction or reversal of methyla-
tion. Furthermore, it is well-known that plant homeodomain
(PHD) zinc fingers, characterized by the Cys4-His-Cys3 mo-
tif, are able to serve as epigenome readers controlling gene
expression via recruitment of multiprotein complexes of
chromatin regulators and transcription factors.68 EF24 and its
congeners have the ability to disrupt zinc fingers by Mi-
chael-guided alkylation of the cysteines in the Cys4-His-Cys3
triads. Thus, several chemical actions dependent on Michael
addition may account for our observations.
EF24 is an oxidant: it operates as a Michael acceptor and binds
GSH and thioredoxin via cysteine sulfhydryl groups and
induces oxidative stress leading to an increase in binding of
DNA and c-Fos/AP-1. Curcumin behaves as a phenolic an-
ti-oxidant inducing anti-inflammatory action, and as a
pro-oxidant that causes apoptosis. As an anti-oxidant, it
quenches ROS and thus reduces free radical reacting capaci-
ties. Conversely, the pro-oxidant activity of curcumin is de-
pendent on the generation of ROS that induces apoptosis. The
mechanisms underlying these two opposite activities are
complex, and the two structures of curcumin (keto and enolic
forms) in solution, position of the hydroxyl group in the
aromatic ring, the presence of transition metal ions, route of
administration, and localized tissue are vital decisive factors
in determining curcumin’s behavior.69
We postulate that the primary anti-cancer action of EF24 is to
cause cellular oxidative stress and induce apoptosis at low µM
concentrations. Further increases in concentration may lead
to rapid cell death predominantly via necrosis, similar to that
induced by phenethyl isothiocyanate (PEITC), found in cru-
ciferous vegetables, and butylated hydroxyanisole (BHA), a
dietary chemopreventive compound.70-71
A second important anti-cancer action of EF24 is inhibition of
NF-κB. We previously demonstrated that EF24 inhibits this
transcription-regulating protein complex by inhibiting IKK
in the cytoplasm.37 The activities of MACs on various kinases
were screened using a 50-kinase panel of the Z’ Lyte in vitro
kinase assay. Among MACs, EF31 more actively inhibits
multiple serine/threonine kinases, most prominently IKKβ,
Akt and kinase insert domain receptor (KDR, a type III re-
ceptor tyrosine kinase) also known as vascular endothelial
growth factor receptor 2 (VEGFR-2). However, EF31 was not
active against p38 and ERK2.38 Gene microarray analysis of
EF24 demonstrated that the compound significantly inhibits
downstream genes of NF-κB transcriptional activation such as
IL1-β, IL-6, IL-8, VEGF and COX-2.
Why should the anticancer drug EF24 increase the
DNA-binding of c-Fos, consequently activate AP-1 and
promote cancer growth and, thereby, counteract the anti-
cancer action of the drug itself? One explanation is that cells
may respond to chemical insult to counteract oxidative stress
in an attempt to simultaneously protect the cells. Support for
this hypothesis can be found in the examples cited below.
PEITC, one of many compounds found in cruciferous vege-
tables, induces a dose-dependent decrease in cell viability
through induction of cell apoptosis and cell cycle arrest in the
G(2)/M phase of DU-145 cells, as does EF24. Both molecules
are electrophiles (as is a Michael acceptor) and interact with
thiols such as GSH. PEITC causes mitochondrial dysfunction,
increases the release of cytochrome c and endonuclease G (an
apoptotic DNAse) from mitochondria, and guides cell apop-
tosis via mitochondria-dependent signaling pathway.70 Die-
tary chemopreventive compounds (isothiocyanates and green
tea polyphenols), phenolic antioxidants such as BHA and its
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metabolite, t-butyl-hydroquinone (tBHQ) used in food pre-
servatives, naturally occurring phytochemicals, such as
PEITC and sulfarophane typically generate cellular oxidative
stress. They modulate gene expression including phase II
detoxifying enzymes glutathione-s-transferase (GST) and
NAD (P) H-quinone reductase (QR) and HO-1 via the anti-
oxidant/electrophile response element (ARE/EpRE).71 We
note that ARE is composed of two adjacent AP-1-like binding
sites and can be activated by Fos/Jun.64
The induction of HO-1 by EF24 parallels a decrease in intra-
cellular GSH, while a sustained reduction in GSH increases
HO-1. In support of this hypothesis, it has been demonstrated
that treatment with the antioxidants N-acetyl-L-cysteine
(NAC) or GSH reduces the expression of HO-1 induced by
cigarette smoke extract (CSE) exposure. AP-1 is a re-
dox-sensitive transcription factor shown in other systems to
regulate HO-1 expression. CSE exposure results in nuclear
accumulation of c-Fos and c-Jun, two key AP-1 components.
Reduction of c-Fos and c-Jun nuclear translocation by the
JNK inhibitor SP-600125 attenuated the CSE-induced ex-
pression of HO-1.72
Finally, the MAC class of compounds differentially activates
the mitogen-activated protein kinases (MAPK; ERK, JNK and
p38) involved in the transcriptional activation of the
ARE-mediated reporter gene. N-acetyl-L-cysteine, GSH and
vitamin E inhibit ERK2 activation and, to a much lesser ex-
tent, JNK 1 activation by BHA and tBHQ, pointing to the role
of oxidative stress. It was suggested that low concentrations of
these chemicals (e.g., BHA, PEITC) activate MAPKs leading
to induction of gene expression (e.g., c-jun, c-fos), which may
protect the cells against toxic insults / enhance cell survival.
At relatively high concentrations, these agents activate both
MAPKS and the ICE/Ced-3 caspase pathway, leading to
apoptosis. Further increase in concentrations leads to rapid
cell death occurring mainly via necrosis 73; cancer cells seem
to respond to EF24 by increasing the DNA binding of c-Fos
and gene expression of several stress genes in a manner simi-
lar to these agents.
Conclusion
In conclusion, we have demonstrated that EF24 increases the
DNA binding of c-Fos. Our data suggest that EF24 triggers a
negative feedback loop through p38 activation to protect cell
survival, which is in agreement with the observation that a
combination of EF24 and SB203580, a p38 inhibitor, syner-
gistically blocks clonogenic activity of cancer cells and in-
duces their apoptosis.40 Modulation of these transcription
factors may reflect cell responses indicative of a struggle for
survival in the process of cell death due to oxidative stress by
EF24. However, the protective actions in cancer cells are
unable to prevail against the insult of oxidative stress, which
induces depolarization of the mitochondrial membrane
leading to apoptosis.
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